Skip to content
2000
Volume 27, Issue 7
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Adverse drug events have been a long-standing concern for the wide-ranging harms to public health, and the substantial disease burden. The key to diminish or eliminate the impacts is to build a comprehensive pharmacovigilance system. Application of the “big data” approach has been proved to assist the detection of adverse drug events by involving previously unavailable data sources and promoting health information exchange. Even though challenges and potential risks still remain. The lack of effective privacy-preserving measures in the flow of medical data is the most important Accepted: one, where urgent actions are required to prevent the threats and facilitate the construction of pharmacovigilance systems. Several privacy protection methods are reviewed in this article, which may be helpful to break the barrier.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612827999210112204732
2021-02-01
2025-07-08
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612827999210112204732
Loading

  • Article Type:
    Review Article
Keyword(s): data privacy; data sharing; Drug use; ethics; pharmacovigilance; policy; social netowork
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test